Anakinra for Neuroinflammation in HIV-1 Infection

Phase 1, open-label, single-arm trial of anakinra in HIV-associated neurocognitive disorder (HAND) and neuroinflammation, sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoints: Frequency and severity of Adverse Events and Serious Adverse Events at Day 112 and Frequency of increases in HIV viral load to greater than or equal to 500 copies/mL at Day 112. Started Aug 2015; status: terminated.